NCT05221398View on ClinicalTrials.gov

Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma

CompletedOBSERVATIONAL
Enrollment

517

Participants

Timeline

Start Date

March 3, 2019

Primary Completion Date

January 18, 2023

Study Completion Date

March 17, 2023

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Immune Checkpoint Inhibitors Based Adjuvant therapy

Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy

OTHER

Active surveillance

Patients in this group only receive active surveillance

Trial Locations (1)

530021

Jian-Hong Zhong, Nanning

All Listed Sponsors
lead

Guangxi Medical University

OTHER

NCT05221398 - Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter